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  INTRODUCTION 
 After the discovery of antibodies over a century ago, early studies 
in the horse made important contributions to the understanding 
of the mammalian adaptive immune system. However, large gaps 
still remain in our knowledge of the equine immunoglobulin (Ig) 
system and this is hampering development of specific vaccines 
and immune-based therapies for many major infectious diseases 
of the horse. Given the economic importance of the horse globally, 
it is vital to build a more detailed understanding of equine Ig func-
tion, as a key first step toward more effective options for treatment 
and prevention of equine diseases. A better understanding of the 
equine IgA (eqIgA) system would seem especially important given 
the numerous equine infections that are manifest in, or gain a foot-
hold at, the mucosal surface.  1   In addition, a wider knowledge of 
IgA systems in different mammals will provide invaluable insights 
into both the variety of functions mediated by this Ab class, and the 
evolution of the IgA system. Moreover, because there are limita-
tions with mouse models of the IgA system (e.g., the mouse lacks 
the main Fc receptor (Fc    RI) responsible for IgA effector func-
tion), it is worthwhile developing a wider knowledge of the IgA 
systems of other mammals so that relevant animal models may 
be identified. For these reasons, we sought to establish systems to 
facilitate molecular characterization of eqIgA. 
 IgA is present in both the serum and mucosal secretions of the 
horse, and it is the principal Ig in milk, tears, and secretions of the 
upper respiratory tract.  2  In common with most other mammalian 
species, the horse has a single IgA heavy chain constant region 
gene (  IGHA ). 3   In contrast, humans, along with chimpanzees, 
gorillas, and gibbons, express two subclasses of IgA (IgA1 and 
IgA2) encoded by distinct heavy chain constant region genes. 
  In mucosal secretions, IgA exists primarily as secretory IgA 
(SIgA). Transepithelial transport of IgA onto the mucosal sur-
faces is mediated by the polymeric Ig receptor (pIgR), a type I 
transmembrane glycoprotein. The pIgR, which is expressed on 
the basolateral surface of epithelial cells, binds to IgA, which has 
been produced by plasma cells in mucosal effector sites. This 
IgA is polymeric (pIgA), comprising two or more IgA mono-
mers joined together by an additional 17     kDa polypeptide, the 
J chain. On binding, both receptor and ligand are internalized 
and transcytosed across a series of vesicular compartments to 
the apical plasma membrane. Here, the extracellular portion of 
the pIgR is cleaved to form secretory component (SC), which 
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remains bound to pIgA as an integral part of the SIgA mol-
ecule. SC provides SIgA with increased resistance to bacterial 
proteases, and through its  N -glycans mediates anchoring to the 
mucosal surface, which enhances the protective role of SIgA.  4  
  SIgA acts as the   “  first line of immunological defense  ”   against 
mucosal infection mediating defense through (i) immune exclu-
sion at the mucosal surface, (ii) pIgA-mediated neutralization 
of pathogens during the process of transyctosis, and (iii) pIgR-
mediated excretion of IgA-containing immune complexes 
formed within the submucosal tissues.  5   In addition, SIgA par-
ticipates in antigen presentation and sampling within mucosal 
tissues, regulation of commensal bacteria, and maintenance of 
mucosal integrity and homeostasis.  6   In the horse, mucosal IgA 
responses seem to have an important role in protection from 
upper respiratory tract pathogens such as equine herpesvirus-1,  7  
equine influenza virus,  8   and   Streptococcus equi.  9  
  The presence of J chain in pIgA is essential for interaction 
with pIgR and, in turn, delivery of pIgA onto mucosal surfaces 
is dependent on pIgR-mediated transepithelial transport. Hence, 
J chain and pIgR are critical components of the mucosal IgA sys-
tem. Proteins consistent with the properties of an equine J chain 
and SC have been described,  10,11   but neither these components 
nor their interaction with equine IgA has been well characterized. 
In this study, we describe the cloning of equine J chain and pIgR, 
the generation of recombinant forms of eqIgA and SC, and analy-
sis of their interaction. Furthermore, through genomic sequence 
analysis we provide an insight into both the chromosomal loca-
tion and gene arrangement of J chain and pIgR, and the potential 
factors involved in regulation of pIgR expression.    
  RESULTS   
  Equine J chain and pIgR complementary DNA (cDNA) 
clones 
  The equine J chain cDNA isolated has an open reading frame 
of 474     bp (Genbank accession no. GQ981317) (  Figure 1 ).  The 
first 22 amino acids are predicted to encode a leader sequence, 
suggesting that the mature protein begins at Gly23 and com-
prises 136 amino acids. The equine J chain amino acid sequence 
showed a high degree of identity to other mammalian J chains, 
with 79, 80, and 74  %   identity to human, cow, and mouse pro-
teins, respectively (  Figure 2a  ). It shows features typical of 
    Figure 1                        Nucleotide sequence and amino acid translation of equine 
J chain. Start of the mature protein at Gly23 is highlighted and indicated by 
an arrow. The single conserved   N  -glycosylation acceptor site is underlined.   
          Figure 2                        J chain sequence analysis. (  a  ) Alignment of the amino acid 
sequences of mammalian J chains. Accession numbers and species 
abbreviations for the sequences used are as follows: human (Hu), NM_
144646; rhesus macaque (Mac), CO646198; cow (Bov), NM_175773; pig 
(Pig), CJ021649; sheep (She), CN823995; dog (Dog), AY081058; rabbit 
(Rab), P23108; mouse (Mo), NM_152839; rat (Rat), XM_341195; and silver 
brushtail possum (Poss), AF091138. The rabbit sequence derives from 
amino acid sequencing of the protein and hence lacks leader sequence. The 
eight conserved Cys residues are shown in bold and those Cys residues 
involved in disulfide bonds with the IgA tailpiece are highlighted and marked 
J-tp. Regions implicated in binding to the secretory component (SC) 
are boxed. The conserved   N  -glycosylation acceptor site is underlined. 
(  b  ) Phylogenetic analysis of the amino acid sequences of mammalian J chains 
(as above) and those from chicken (AB076374), red-eared slider turtle 
(AB085611), bullfrog (B-frog; AF157508), African-clawed frog (Ac-frog; 
AF036547), nurse shark (AF516711), and clear-nosed skate (AF520475).   612  VOLUME 3 NUMBER 6 | NOVEMBER 2010 | www.nature.com/mi
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J chain such as a preponderance of acidic residues, a single con-
served  N -glycosylation site, and eight Cys residues, involved in 
intra- and interchain disulfide bond formation, conserved in 
all known mammalian J chain sequences. In common with a 
J chain protein isolated from reduced and alkylated equine IgM,  11  
the predicted amino acid sequence for mature equine J chain 
lacks methionine. Phylogenetic analysis (  Figure 2b )  showed 
equine J chain to segregate with other mammalian sequences 
but to form a separate branch, reflecting the fact that the family 
equidae is a member of the order perissodactyla, rather than 
the order artiodactyla (even-toed ungulates), which includes 
cattle, sheep, and pigs. 
 EqpIgR cDNA comprised an open reading frame of 2,292   bp 
(Genbank accession no. GQ981318) (  Figure 3a  ). The first 18 
amino acids are predicted to encode an N-terminal leader 
sequence, indicating that the mature protein begins at Lys19 
and comprises 746 amino acids. A comparison of eqpIgR with 
those of other mammalian species (  Figure 4  ) reveals a high 
similarity in amino acid sequence and structural organization. 
Similar to other pIgRs, the eqpIgR comprises an N-terminal 
extracellular region of five Ig-like domains (D1  –  5) and one 
non-Ig-like domain (D6), a short membrane spanning region, 
and a long C-terminal cytoplasmic tail. Furthermore, the Ig-like 
domains of eqpIgR show the conserved Cys residues involved 
in intradomain disulfide bonds observed in pIgRs from other 
species.  12  The number of potential  N -glycosylation sites differs 
between species and none of the sites are conserved in all spe-
cies. There are four putative  N -glycosylation sites in the eqpIgR 
compared with seven in human, eight in mouse, four in rat, 
three in bovine, and two in rabbit pIgR. The overall amino acid 
identity of the eqpIgR with human, bovine, and mouse proteins 
is 65, 63, and 57  %  , respectively. However, regions with func-
tional significance, such as those involved in interaction with 
IgA, and regions of the cytoplasmic domain that govern recep-
tor endocytosis and trafficking  12   are more highly conserved 
(see   Figure 4 ).  Phylogenetic  analysis  ( Figure 3b  ) showed the 
eqpIgR to cluster with the cow, pig, and dog pIgR, but to form 
a separate branch, again illustrating phylogenetic distance from 
the even-toed ungulate family.     
  Purification and analysis of recombinant eqIgA (reqIgA) 
  An expression vector to drive expression of an      heavy chain 
(HC) comprising a mouse V  H  domain followed by the C  1, hinge, 
C    2, and C    3 domains of eqIgA was constructed. Transfection 
of mouse      light chain (LC)-expressing CHO-K1 cells with this 
HC vector resulted in the expression of eqIgA, which bound its 
cognate antigen 3-nitro-4-hydroxy-5-iodophenylacetate (NIP) and 
was recognized by anti-mouse    LC and anti-horse IgA antibodies. 
Analysis of affinity-purified reqIgA by size exclusion chroma-
tography and sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE;   Figure 5a – c ) was consistent with 
covalently stabilized monomers (H  2 L 2  ). Despite the absence 
of a Cys residue within the CH1 domain with which to form a 
HC  –  LC disulfide bond, LC and HC dimers were not observed. 
However, unlike human IgA, three Cys residues are present 
within the hinge region of eqIgA, the most N-terminal of which 
may form a covalent bond with the LC. EqIgA purified from 
serum, which was included for comparison, ran predominantly 
as dimer with some monomer and higher polymer. This obser-
vation is consistent with previous reports that equine serum IgA 
is predominantly dimeric.  10,13  Human IgA1 and IgA2 have two 
common  N -glycosylation sites, one within the CH2 domain and 
the other within the C-terminal 18 amino acid tailpiece. These 
conserved   N  -glycosylation sites are present within eqIgA and 
treatment of recombinant monomeric eqIgA (reqmIgA) with 
  N -glycanase to remove  N -linked sugars ( Figure 5c ) resulted in 
a decrease in the size of the IgA HC, suggesting that these sites 
are occupied in eqIgA. 
  Transfection of the reqmIgA-producing CHO clone with the 
J chain expression vector resulted in the expression of IgA of 
multiple molecular forms (  Figure 5d  –  f ),  including  covalently 
stabilized monomer (H  2 L 2 ), dimer (H  4 L 4 J), and larger polymers. 
This finding is consistent with previous studies of the coexpres-
sion of human IgA and J chain in mammalian cells, which have 
shown that production of IgA polymers is not 100 %  efficient.  14,15  
Generation of dimeric IgA (dIgA) and pIgA was consistent with 
J chain incorporation, although the J chain itself could not be 
directly identified because of lack of a suitable detection anti-
body. However, recombinant dimeric equine IgA (reqdIgA)-pro-
ducing CHO clones were selected on the presence of antibody 
that could bind to human SC (hSC), for which the presence of 
J chain is an absolute requirement.  16    
  Analysis of recombinant eqSC (reqSC) 
  To produce a recombinant form of the pIgR equivalent to SC, 
the eqpIgR cDNA was truncated by introduction of a stop codon 
immediately after that encoding Asp590 in D6. A potential cleav-
age site has previously been identified here (see   Figure 4 )  and 
used for the truncation of recombinant human and mouse pIgR 
in earlier studies.  14,17   Transfection of CHO-K1 cells with eqSC 
cDNA resulted in the secretion of eqSC protein into supernatant. 
Positive clones were selected on the basis of reqdIgA binding 
capacity, providing preliminary evidence that the recombinant 
form of eqSC was able to bind its dIgA ligand. SDS-PAGE 
analysis revealed that purified reqSC had a molecular mass 
of approximately 75     kDa (  Figure 6  ) and was recognized by a 
mouse anti-human SC antibody (  Figure 6b  ). reqSC migrated 
slightly faster than the recombinant form of hSC (rhSC), prob-
ably because of differences in glycosylation, as mentioned above. 
The recognition of reqSC by concanavalin A (data not shown) 
confirmed its glycosylation status. Both reqSC and rhSC were 
able to bind reqdIgA ( Figure 6c ) and recombinant human dIgA1 
(rhdIgA1;   Figure 6d  ), consistent with earlier studies that have 
described the interspecies binding of SC and dIgA from human 
and other mammals.  17,18    
  Surface plasmon resonance analysis of dIgA  –  SC interactions 
 Injection  of  20   n m   of  reqdIgA  or  rhdIgA1  over  immobilized 
NIP  –  bovine serum albumin gave a response of   ~  400     RU with 
a  variation  between  cycles  of      <    10   RU.  Subsequent  binding  of 
reqSC to both the equine and human form of dIgA fitted a 
1:1 Langmuir binding model (  Figure 7a  –  c  ), in keeping with MucosalImmunology | VOLUME 3 NUMBER 6 | NOVEMBER 2010   613
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      Figure 3                        Polymeric Ig receptor (pIgR) sequence analysis. (  a  ) Nucleotide sequence and amino acid translation of equine pIgR. Start of the 
mature protein at Lys19 is highlighted and indicated by D1. The start of each of the extracellular domains, D1  –  6 and the transmembrane (TMB) 
and cytoplasmic (Cyt) domains are highlighted and labeled. Putative   N  -glycosylation acceptor sites are underlined. (  b  ) Phylogenetic analysis of the 
amino acid sequences of various mammalian pIgRs. Accession numbers of the sequences used are as follows: human, X73079; cow, X81371; pig, 
AB032195; dog, AY081057; rabbit, X00412; mouse, NM_011082; rat, NM_012723; silver brushtail possum, AF091137; tammar wallaby, AF317205; 
chimpanzee, XM_514153; orangutan, CR859163; rhesus macaque, XM_001083307; chicken; XM_417977; African clawed frog, EF079076; Fugu, 
AB176853; and zebra fish, XM_689741. The sequence for common carp was from Rombout   et al  .  53     614  VOLUME 3 NUMBER 6 | NOVEMBER 2010 | www.nature.com/mi
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            Figure 4                        Alignment of the amino acid sequences of mammalian polymeric Ig receptor (pIgR). Accession numbers and species abbreviations for the 
sequences used are as follows: human (hu), X73079; cow (bo), X81371; pig (pig), AB032195; dog (dog), AY081057; rabbit (rab), X00412; mouse (mo), 
NM_011082; rat (rat), NM_012723; silver brushtail possum (bp), AF091137; and tammar wallaby (tw), AF317205. Cysteines involved in intradomain 
disulfide bonds are shown in bold. The Cys residue that forms a disulfide bond with IgA is highlighted.   N  -glycosylation acceptor sites are underlined. 
Complementarity determining region (CDR)-like loops in D1, secretory component (SC) cleavage site in D6, and regions involved in basolateral and 
androgen responsive-element (ARE) targeting and endocytosis are boxed and labeled.   MucosalImmunology | VOLUME 3 NUMBER 6 | NOVEMBER 2010   615
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the known 1:1 stoichiometry between human pIgA and SC. 
Consistent with studies in other species, we found that eqSC 
was unable to bind to mIgA, regardless of whether it was equine 
or human. This finding supports early reports that a molecule 
consistent with SC associated only with high-molecular-weight 
species  of  IgA  (    >    350   kDa)  in  equine  secretions. 10   Equine  SC 
bound to reqdIgA with a K  D   of  5.1 × 10     −     9     m   and  to  rhdIgA1 
with a K  D  of 1.4 × 10     −     9     m , consistent with earlier reports 18  of the 
binding of human pIgA to SC from various species (human, 
bovine, and rabbit) with K  D   values ranging from 1.3  ×  10      −     9   to 
3.2 × 10     −     9     m . The slightly lower affinity of reqSC for reqdIgA was 
almost entirely because of a slower rate of association with the 
equine  (2.5 × 10 7     m       −     1    min     −     1  ) when compared with the human 
(5 × 10 7     m       −     1    m i n      −     1 )  ligand. 
        Figure 5                        Analysis of recombinant IgAS. (  a  ) Size exclusion chromatography (fast protein liquid chromatography (FPLC)) analysis of recombinant equine 
IgA affinity purified from supernatant of CHO-K1 cells transfected with heavy chain (HC) and light chain (LC) vectors, showing a single peak corresponding 
to monomeric IgA. (  b, c  ) Immunoblot analysis of equine serum IgA (sIgA) and recombinant monomer IgA (mIgA) probed with goat anti-equine IgA 
under nonreducing and reducing conditions, respectively. (  d  ) Size exclusion chromatography (FPLC) analysis of recombinant equine IgA affinity purified 
from supernatant of CHO-K1 cells transfected with LC, HC, and J chain vectors, showing peaks corresponding to mIgA, dimer (dIgA), and larger 
polymers (pIgA). (  e, f  ) Immunoblot probed with goat anti-equine IgA and Coomassie stain of sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) gel, respectively, of affinity-purified recombinant equine IgA (rIgA) from cells transfected with LC, HC, and J chain, before size exclusion 
chromatography (FPLC) showing bands corresponding to mIgA, dIgA, and pIgA, and after FPLC separation into mIgA (rmIgA) and dIgA (rdIgA) fractions. 
sIgA is included for comparison. In   a   and   d,   minor peaks eluting at   ~  7    ml correspond to antibody aggregated during the purification process.   
          Figure 6                        Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of recombinant equine secretory component (SC). (  a  ) 
Gel stained with PageBlue. (  b    –    d  ) Immunoblots probed with (  b  ) mouse anti-human SC, (  c  ) recombinant dimeric equine IgA (reqdIgA), and 
(  d  ) recombinant human dIgA1 (rhdIgA1). For each panel, the recombinant form of human SC (rhSC) is shown in the left lane and recombinant 
equine SC (reqSC) in the right lane.   616  VOLUME 3 NUMBER 6 | NOVEMBER 2010 | www.nature.com/mi
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  Preincubation of reqSC with polyclonal serum eqIgM was 
found to inhibit the binding of reqSC to immobilized reqdIgA 
(  Figure 7d ), indicating that reqSC can also bind to eqIgM with 
appreciable  affinity.   
  Analysis of the equine J chain and eqpIgR genomic DNA 
  Searches of the equine genome with equine J chain and eqpIgR 
cDNA sequences identified sequences on   Equus caballus   chro-
mosome 3 (ECA3) and ECA5, respectively. Human and mouse 
J chain and   PIGR   genes have been localized to HSA4 (  Homo 
sapiens   chromosome 4) and MMU5 (  Mus musculus   chromo-
some 5) and HSA1 and MMU1, respectively.  19 – 22  Comparative 
mapping of the human, mouse, and equine genomes has 
aligned regions of HSA4 and MMU5 to ECA3 and regions 
of HSA1 and MMU1 to ECA5  23,24   providing support for our 
assignment of the equine genes. Close to the human   PIGR  
gene on chromosome 1q31  –  q42 are the Fc receptors for IgG 
(Fc   R),  IgE  (Fc  RI),  and  IgA / IgM  (Fc   /     R). We located a 
receptor homologous to human and mouse Fc    /    R  (acces-
sion no. XM_001489848) downstream of   PIGR  , and a recep-
tor homologous to mammalian Fc    RIII as well as the equine 
Fc   R1     -chain are located on ECA5, suggesting comparable 
arrangement of genes in the horse. 
  Exon number, length, and exon  –  intron boundaries of the 
equine J chain and   PIGR   genes bear a close resemblance to 
those of human and mouse,  22,25 – 27   with the coding sequence 
of J chain distributed across 4 exons and that of pIgR across 11 
exons (  Figure 8 ). 
  The proximal promoter region and exon 1 of the eqpIgR 
gene were compared with human (Y08254), rat (AF039920), 
and mouse (U83426) sequences to identify conserved bind-
ing sites for transcription factors.  28,29   DNA elements previ-
ously implicated in regulation of basal transcription of pIgR 
mRNA were identified (  Figure 9a  ), including an E-box motif, 
activator protein 2 binding site, and an inverted repeat motif 
in the proximal promoter region. Binding sites for inducible 
factors included a conserved interferon-sensitive response 
element in exon 1 and steroid-responsive elements, includ-
ing an androgen responsive-element in exon 1 and a gluco-
corticoid DNA-responsive element in the proximal promoter 
region. Interestingly, two interferon-sensitive response ele-
ments approximately 100     bp upstream of the transcription 
start site are conserved between the horse and human but are 
lacking in the rodent pIgR genes. As the interferon-sensitive 
response element motif is a binding site for the interferon 
regulatory factor family of cytokine-inducible transcription 
factors, these evolutionary differences of rodent from both 
human and horse may reflect differences in pIgR regulation 
by proinflammatory cytokines such as interferon-     and tumor 
necrosis factor. 
  Intron 1 of the   eqpIgR   gene was compared with those of 
the human (accession no. X95880) and mouse (accession 
no. AB001489) to identify a conserved intronic enhancer 
(  Figure 9b  ). This enhancer region contains at least seven 
target elements for DNA-binding factors.  28,29   All seven ele-
ments were identified within intron 1 of the eqpIgR, includ-
ing conserved binding sites for tissue-specific (hepatocyte 
nuclear factor-1) and cytokine-inducible transcription fac-
tors (signal transducer and activator of transcription 6 and 
nuclear factor-   B).    
      Figure 7                        Surface plasmon resonance analysis of the equine secretory 
component(eqSC)  –  dimeric IgA (dIgA) interaction. (  a  ) Normalized 
sensorgram showing the binding of recombinant dimeric equine IgA 
(reqdIgA; black) and recombinant human dIgA1 (rhdIgA1; dark gray), 
both at 20    n  M  , to a NIP-derivatized sensor chip and the subsequent 
application of recombinant eqSC (reqSC) (133    n  M  ) or buffer (light gray line). 
(  b, c  ) Sensorgrams (black lines) for the binding of reqSC (at concentrations 
of 4.1, 8.3, 16.6, 33, 66, and 133    n  M  ) to prebound (  b  ) reqdIgA and 
(  c  ) rhdIgA1. The gray line represents the binding of reqSC to either 
prebound (  b  ) reqmIgA or (  c  ) rhmIgA1. (  d  ) Inhibition of eqSC binding 
to immobilized dIgA by preincubation of eqSC with equine serum IgM. 
Results are shown as the percentage of maximum response observed in 
the absence of inhibition.    MucosalImmunology | VOLUME 3 NUMBER 6 | NOVEMBER 2010   617
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  DISCUSSION 
  SIgA provides a   “  first line  ”   of immune defense, critical for the 
protection of mucosal sites that are vulnerable to attack by 
infectious microorganisms. In this study we report the cloning 
of equine J chain and pIgR, thereby completing the cloning of 
all three specific components of equine SIgA, namely IgA HC, 
J chain, and SC. In addition, we document the first expression of 
these three components in recombinant form, with subsequent 
functional characterization. 
 The recombinant version of eqIgA appeared representative of 
its native counterpart and assembled as anticipated.  10   An  early 
study suggested that not all eqIgA molecules have covalent 
links between LC and HC,  13  but this was not observed to be the 
case with reqIgA. It is possible that these different observations 
reflect allotype differences between the IgAs analyzed, given 
the example in mouse IgA, in which different allotypic forms 
differ in their ability to form H-L disulfide bonds.  30   Certainly, 
allelic variation of IgA has been observed in equine genomic 
DNA,  31  although it is presently unclear whether any differences 
lie within coding regions. 
 Molecular models of human IgA1 and IgA2  32,33  have revealed 
a striking effect of hinge length on antibody structure. The 
shorter hinge region (6 residues) of human IgA2 enforces a more 
compact structure on the IgA2 molecule compared with that of 
IgA1, which has a more extended hinge region (19 residues). 
Horse IgA has a relatively long hinge (11 residues) but the pres-
ence of three Cys residues suggests that it may be constrained 
by inter-H-chain disulfide bonds. The extended human IgA1 
hinge is thought to provide this subclass with a capacity for 
more avid binding to antigens spread further apart across the 
surface of pathogens. Possibly, such a capacity is of less impor-
tance in mammals such as the horse, in which both SIgA and 
serum IgA are found chiefly in dimeric form. The proposed 
structure of dIgA is of two IgA monomers linked tail to tail via 
J chain,  34   an arrangement clearly compatible with the ability to 
bind widely spaced antigens through at least one of the Fab arms 
of each monomer. 
  To facilitate production of polymeric eqIgA, we cloned 
equine J chain. Its sequence contains the conserved Cys resi-
dues (see   Figure 2  ) required for covalent interaction with 
the IgA tailpiece Cys,  34,35   and we found that it was able to 
promote efficient polymerization of eqIgA. The conserved 
nature of the J chain Cys residues across diverse species 
(human, mouse, chicken, and bullfrog) seems sufficient 
to promote dimerization when heterogenously expressed 
with human IgA.  36   However, the degree of polymerization 
    Figure 8                        Gene organization. Structure of the (  a  ) equine J chain and (  c  ) pIgR genes, and comparison of (  b  ) equine J chain and (  d  ) pIgR exon  –  intron 
boundaries with those of the human and mouse genes. Equine J chain coding sequence is arranged as follows: exon 1, 97    bp encoding 33    bp 
untranslated region (UTR) and the first 21 residues of the leader peptide; exon 2, 126    bp encoding the last amino acid of the leader peptide and 
amino acids       +      1  –  41; exon 3, 81    bp encoding amino acids 42  –  68; and exon 4, 1.1    kb encoding amino acids 69  –  136 (205    bp) and a long 3     UTR. 
Equine polymeric Ig receptor (pIgR) coding sequence is arranged as follows: exon 1, 128    bp of 5     UTR; exon 2, 97    bp encoding 5     UTR and 14 amino 
acids of the leader peptide; exon 3, encodes 4 amino acids of the leader peptide and all of D1; exon 4, encodes D2 and D3; exon 5, encodes D4; 
exon 6, encodes D5; exon 7 encodes D6; exon 8 encodes the last 5 amino acids of D6, the transmembrane (TMB) and the first 8 amino acids of 
the cytoplasmic domain; exons 9 and 10, encode the cytoplasmic domain; and exon 11 encodes the last 31 amino acids of the cytoplasmic tail and 
1,700    bp of 3     UTR. Numbering shown in   b   and   d   is relative to the start of the mature protein.   618  VOLUME 3 NUMBER 6 | NOVEMBER 2010 | www.nature.com/mi
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is variable, suggesting that subtle amino acid differences 
between species may influence the efficiency of interac-
tion. Indeed, additional residues within the tailpiece and 
the C    3 domain of IgA seem to have a role in polymeriza-
tion.  35,37   Through incorporation of equine J chain, rather than 
J chain from another mammalian species, our expression sys-
tem offers the advantage of producing authentic versions of 
polymeric eqIgA, suitable for in-depth analysis from which 
reliable conclusions relevant to the horse may be drawn. 
  Separate to its role in IgA polymerization, J chain seems to 
be required for the binding of dIgA to pIgR  /  SC through direct, 
noncovalent interactions involving a C-terminal loop com-
prising Cys109 to Cys134 (human numbering) and two other 
regions (boxed in   Figure 2 ). 36   These elements are observed to 
be well conserved in equine J chain. 
  Turning to the role of pIgR, the binding of dIgA to pIgR 
involves both covalent and noncovalent interactions. Three loops 
within pIgR D1 that are analogous to the complementarity deter-
mining regions of Ig variable domains are critical for noncovalent 
interaction with dIgA.  18,38  These complementarity determining 
region-like loops are conserved in eqpIgR ( Figure 4 ). After non-
covalent binding between IgA and pIgR, a covalent bond is formed 
between the pIgR and one of the IgA monomer subunits. In the 
human system, the Cys residues involved in this covalent bond are 
Cys468 in the pIgR D5 and Cys311 within the C  2 domain of IgA. 
These Cys residues are conserved in eqpIgR ( Figure 4 ). 
      Figure 9                        Identification of transcription factor binding sites. (  a  ) Alignment of the 5     flanking region and exon 1 of the horse, human, rat, and mouse 
  PIGR   showing binding sites for constitutive and inducible transcription factors. AP2, activator protein 2; ARE, androgen response element; GDRE, 
glucocorticoid DNA-response element; tissue-specific, sequence that may have a role in tissue-specific regulation; ISRE, interferon-sensitive response 
element; repeat, inverted repeat motif; TATA, non-consensus TATA-box. Numbering shown is relative to the transcriptional start shown by gray highlight. 
(  b  ) Alignment of the   PIGR   intron 1 enhancer from horse, human, and mouse showing the seven regulatory elements identified in this region, including 
hepatocyte nuclear factor (HNF-1), signal transducer and activator of transcription 6 (STAT-6), and nuclear factor (NF)-    B binding sites.   MucosalImmunology | VOLUME 3 NUMBER 6 | NOVEMBER 2010   619
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 Of the HC domains of IgA, the C  3 domain shows the highest 
degree of identity across species and seems to be the most impor-
tant for noncovalent interaction with pIgR.  14,39  Motifs within the 
C    3 domain of IgA required for pIgR binding are centered on 
three regions. In human IgA these include a loop region compris-
ing  residues  402 – 410,  adjacent  residues  411 – 414,  Lys377,  and 
residues  Pro440 – Phe443,  the  so-called   “ PLAF ”   loop. 14,40   In the 
horse, 15 of these 18 amino acids are conserved or highly con-
served substitutions, suggesting a common mode of binding. 
 The pIgR from certain species (human and cow) can bind and 
transport pIgM as well as pIgA, whereas pIgR from rabbits and 
rodents transports only pIgA.  12,36  Our preliminary results with 
a polyclonal preparation of eqIgM suggest that pIgR in the horse 
also binds pIgM. However, further detailed studies, ideally using 
recombinant eqIgM, will be required to ascertain the precise 
affinity of eqSC for eqIgM. 
  In humans, transcytosis of pIgR occurs in the absence of its 
IgA ligand, resulting in release of free SC into secretions in which 
it acts to inhibit the binding of bacteria and bacterial toxins to 
intestinal cells.  41  In addition, free SC produced by bronchial epi-
thelial cells has a regulatory role by complexing with and seques-
tering soluble interleukin-8. Thus, SC may form part of a feedback 
mechanism that downregulates interleukin-8-mediated recruit-
ment of neutrophils to the airway and attenuates the inflamma-
tory response.  42  The presence of free SC in equine milk  10  suggests 
that constitutive release of free SC into the secretions also occurs 
in horses. Given the upregulation of interleukin-8 and its role in 
promoting airway neutrophilia in horses with recurrent airway 
obstruction,  43  it would be interesting to investigate the existence 
of this feedback mechanism in horses. 
  Efficient export of pIgA into the secretions requires coordi-
nated transcriptional regulation of pIgR expression by a number 
of mediators.  28,29  We found that many of the binding sites for tran-
scription factors identified within the proximal promoter region, 
exon 1, and intron 1 of the human  PIGR  gene are conserved in the 
horse  PIGR  gene. These include the interferon-sensitive response 
element (exon 1), nuclear factor-  B (intron 1), and signal transducer 
and activator of transcription 6 (intron 1) sites that are required 
for interferon-    , tumor necrosis factor, and interleukin-4-
mediated upregulation of pIgR mRNA. Thus, it seems likely that 
these cytokines similarly have a role in the horse, in regulation of 
pIgR expression at sites of infection and inflammation. 
  The effector functions of equine IgA are not yet well char-
acterized. However, evidence of strong opsonophagocytic 
activity, for example, against the important pathogen   S. equi , 9  
suggests that equine IgA is able to mediate killing through FcR 
on phagocytes or through the complement pathway. Indeed, 
a receptor for eqIgA homologous to human CD89 (Fc   RI)  is 
readily detected in equine polymorphonuclear neutrophils and 
is able to bind equine serum IgA and SIgA.  44  Interestingly, com-
parisons between human, bovine, and equine CD89 suggest 
that although their interaction sites for IgA are related, each 
has distinct features.  44   Thus, to gain insights into this interac-
tion in a particular species, it is essential to investigate the IgA 
and receptor in that species, rather than making assumptions 
based on studies in other species. The availability of reqIgA now 
opens up the possibility of both defining the precise interaction 
site on eqIgA Fc for eqCD89, and further elucidating the killing 
mechanisms that eqIgA is capable of triggering. 
 A mucosal IgA response in horses makes a key contribution to 
immunity against viral (equine influenza virus and equine herpes-
virus-1) and bacterial ( S. equi ,  Rhodococcus equi ,  Salmonella enterica , 
and  Clostridium botulinum ) infections. 7 – 9,45 – 48  Our studies pave 
the way for development of pathogen-specific reqIgA suitable for 
therapeutic intervention in the horse, mirroring developments in 
the human system in which recombinant hIgAs targeting various 
bacterial, viral, and parasitic antigens are under analysis. Mucosal 
administration of reqIgA could prevent or treat equine infectious 
disease in which effective vaccines are unavailable or provide only 
partial protection, such as  R. equi  pneumonia in foals. 
 IgA also acts as an architect of the mucosal immune response 
by participating in antigen presentation to mucosal dendritic 
cells and induction of appropriate T-cell responses and immu-
nological memory.  6   In addition to a role in protection against 
pathogenic microorganisms, a significant role for IgA in shaping 
and regulating the population of commensal bacteria within the 
mucosa has been recognized. The availability of defined recom-
binant versions of eqIgA should now facilitate studies into these 
phenomena in the horse. 
  In conclusion, we have produced and characterized the first 
reqIgA to reflect the different molecular forms found in nature, 
namely polymeric and secretory eqIgA. These show both similari-
ties with other mammalian IgA, and important species-specific 
distinctions. The latter underline the value of detailed investiga-
tions within particular species, and caution against simple extrap-
olation of findings in one species to another. The recombinant 
eqIgA, J chain, and SC described in this study are valuable sources 
of pure and homogenous material that can be used as reference 
proteins for the production and screening of equine-specific mon-
oclonal antibody reagents. Furthermore, production of reqIgA of 
defined specificity and molecular form will permit delineation 
of the precise functions of IgA in equine immunity, and open up 
possibilities for development of pathogen-specific reqIgA suitable 
for therapeutic intervention in equine infectious disease.    
  METHODS         
  Cloning equine J chain and pIgR   .     cDNA synthesized from equine 
ileal total RNA using the ImProm II Reverse Transcription System 
(Promega, Southampton, UK) was used as template for PCR ampli-
fication of J chain and pIgR using degenerative primers based on the 
known nucleotide sequences from other mammalian species (detailed 
in  Table 1 ). After sequencing of J chain and pIgR PCR products, 5    / 3   
RACE was carried out using total ileal RNA and a 5    /  3     RACE kit 
(Roche, Manheim, Germany). Forward and reverse primers ( Table 1 ) 
were designed according to the 5   / 3   RACE sequences and the complete 
J chain and pIgR coding sequences were amplified from cDNA. J chain 
and pIgR PCR products were cloned, respectively, into pcDNA3.1 
(Invitrogen, Paisley, UK) and pcDNA3.1  /  Hygro (Invitrogen) and 
sequenced as before. Amino acid sequence analysis was carried 
out using ClustalW (  http://www.ebi.ac.uk/clustalW/index.html  ). 
Phylogenetic analysis was performed using the neighbor-joining 
method with 1,000 bootstrap replications available in MEGA3 molecu-
lar evolutionary genetics analysis software.  49    620  VOLUME 3 NUMBER 6 | NOVEMBER 2010 | www.nature.com/mi
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  Expression of monomeric and dimeric equine IgA in CHO-K1 cells   .  
    Genomic DNA for the horse   IGHA   gene 3   was amplified by PCR and 
subcloned as a  Bam HI fragment downstream of a mouse V  H  gene specific 
for NIP in the vector pcDNA3.1VNip.  50  To produce reqmIgA, CHO-K1 
cells expressing a mouse      LC specific for NIP were transfected with 
the IgA HC vector, using previously described protocols.  51  Supernatant 
from individual resistant CHO clones was screened for IgA production 
by antigen-capture enzyme-linked immunosorbent assay as previously 
described,  51  except that detection antibodies used were either goat anti-
mouse      LC-horseradish peroxidase (HRP) conjugate (0.2        g   ml     −     1 ; 
Bethyl Laboratories, Montgomery, TX) or goat anti-horse IgA-HRP 
conjugate (0.1     g   ml     −     1 ; Serotec, Oxford, UK). 
  To produce reqdIgA, a CHO-K1 cell line stably producing reqmIgA 
was transfected with the equine J chain expression vector. Supernatant 
from individual resistant CHO clones was screened for dIgA production 
using a hSC capture enzyme-linked immunosorbent assay,  14   detecting 
with goat anti-mouse    LC-HRP (0.2     g   ml     −     1 ; Bethyl Laboratories).   
  Purification and analysis of reqIgA   .    reqIgA  was  purified  using  NIP-
affinity chromatography and size exclusion chromatography as previously 
described.  14,51   Fractions corresponding to intact monomeric (H  2 L 2 )  or 
dimeric (H  4 L 4  J) eqIgA were pooled for further analysis by SDS-PAGE 
and western blotting. Equine IgA from serum (Accurate Chemical and 
Scientific Corporation, Westbury, NY) was included for comparison. 
Gels were stained with Coomassie brilliant blue and western blots were 
probed with HRP-conjugated goat anti-horse IgA (0.1     g   ml     −     1 ; Serotec). 
Using a GlycoPro enzymatic deglycosylation kit (Prozyme, Leandro, CA), 
  N -linked sugars were removed from reqmIgA.    
  Expression of reqSC in CHO-K1 cells   .   A truncated form of equine pIgR 
cDNA, equivalent to the coding sequence for SC, was amplified using 
the pIgR forward primer B and SC reverse primer (  Table 1 ),  inserted 
into pcDNA3.1 / Hygro and sequenced. ReqSC was expressed in CHO-K1 
cells, as previously described for rhSC.  14   Supernatant from individual 
resistant CHO-K1 clones was screened for SC production by dotblot on 
nitrocellulose, detecting bound reqdIgA with HRP-conjugated goat anti-
mouse    LC (0.2     g   ml     −     1  in phosphate-buffered saline with Tween 20).   
  Purification and analysis of reqSC   .   reqSC was purified using a human 
pIgA-Sepharose column as previously described,  14  and analyzed by SDS-
PAGE and western blotting. Gels were stained with PageBlue protein stain-
ing solution (Fermentas, St Leon-Rot, Germany) and western blots were 
probed with rhdIgA1 or reqdIgA (both 1     g   ml     −     1 ) followed by goat anti-
LC-HRP (0.2        g   ml     −     1  ), or mouse anti-human SC (1       g   ml     −     1 ;  Monosan, 
Uden, The Netherlands) followed by goat anti-mouse Fc-HRP (1  /  1,000; 
Sigma-Aldrich, Poole, UK). rhSC  14  was included as a comparison.    
  Interaction of IgA with reqSC   .    Surface  plasmon  resonance  experi-
ments were carried out on a BiacoreX instrument (GE Healthcare, Little 
Chalfont, UK) with NIP-derivatized bovine serum albumin immobilized 
onto a CM5 chip. Either reqdIgA or hdIgA1 (100     l, 20   n m ) was applied at 
a flow rate of 30     l   min     −     1 . reqSC at concentrations up to 133   n m  (100     l, 
flow rate of 30        l   min     −     1  ) was then applied and binding to the prebound 
IgA analyzed. To determine whether reqSC can bind eqIgM, the effect 
of preincubating reqSC with polyclonal serum eqIgM (0 – 200     g   ml     −     1 ) 52  
on its ability to bind to prebound reqdIgA was assessed. BIAevaluation 
3.2 software (GE Healthcare) was used for data analysis.    
  Analysis of equine J chain and pIgR genomic DNA sequences   .    E q u i n e  
J chain and pIgR cDNA sequences were used to search the equine genome 
(available at  http://www.ncbi.nlm.nih.gov/Genbank ) for corresponding 
genomic DNA sequences. The putative transcriptional start sequences 
and intron – exon arrangements were identified by comparison of cDNA 
and genomic sequences. Conserved transcription regulatory elements in 
the equine pIgR gene were identified by comparison with human, mouse, 
and rat  PIGR  g e n e s .        
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